Time: September 13-16, 2022

Topic: Revolutionizing Genetic Therapy Development & Delivery to the Eye

Location: Double Tree by Hilton Boston North Shore, 50 Ferncroft Rd, Danvers, MA 01923, United States

The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Join 40+ speakers from the industry leaders in ophthalmic gene therapy as we discover novel vector engineering, disease models, clinical trials design, patient enrolment platforms and more.

Join 150+ stake holders within the industry to overcome these challenges and get these drugs to the ophthalmic gene therapy patients who needs them as fast as possible.

Let's Meet at the 3rd Annual Gene Therapy for Ophthalmic Disorders in September!

As a comprehensive contract research organization (CRO) solution provider, Cyagen recognizes ophthalmic diseases as a breakthrough point for gene therapy and has established an ophthalmic gene therapy platform to overcome the above obstacles. We have equipped the platform with state-of-the-art ophthalmic instruments for small animals and an experienced professional team. With 16 years of gene editing model construction experience, Cyagen can provide you with an array of standardized preclinical research solutions for ophthalmic gene therapy.

Attendees are encouraged to participate in our Lucky Draw and visit our booth to pick-up your prizes!

Why Choose Cyagen?

  • 15+ years' experience in custom animal model generation
  • 78,000+ animal models generated and delivered worldwide
  • 6,200+ citations in SCI journals
  • 3,000+ university and company partners
  • 100% money-back guarantee option available for most services
  • AAALAC-Accredited and OLAW Assured